Navigation Links
Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
Date:1/12/2009

HOPKINTON, Mass., Jan. 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. today announced that on January 8, 2009, it received notice from the NASDAQ Stock Market ("NASDAQ") that for the last 10 consecutive trading days, the market value of its listed securities has been below the minimum $35 million requirement for continued inclusion under NASDAQ Marketplace 4310(c)(3)(B). Furthermore, NASDAQ stated that the Company does not comply with NASDAQ Marketplace Rule 4310(c)(3)(A) or 4310(c)(3)(C), which requires the Company to have either minimum stockholders' equity of $2.5 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )

In accordance with NASDAQ Marketplace Rule 4310(c)(8)(C), the Company was provided thirty calendar days, or until February 9, 2009 (the "Compliance Period"), to regain compliance. This requires, at a minimum, that the market value of listed securities of the Company's common stock remain $35,000,000 or more for a minimum of 10 consecutive business days at anytime prior to February 9, 2009.

If the Company does not regain compliance within the Compliance Period, NASDAQ will provide the Company with written notification that the Company's common stock will be delisted from the NASDAQ Capital Market. At that time, the Company may appeal the determination by the NASDAQ Staff to delist its common stock to a Listing Qualifications Panel. The Company is currently considering actions that may allow it to regain compliance with the NASDAQ continued listing standards and maintain its NASDAQ listing. There is no assurance that the Company will be able to take any of these actions or that any of the actions will be sufficient to allow the Company's NASDAQ listing to continue or for how long such listing will continue. If the Company is unsuccessful in maintaining its NASDAQ listing, then the Company may pursue listing and trading of the Company's common stock on the Over-The-Counter Bulletin Board or another securities exchange or association with different listing standards than NASDAQ.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's ability to obtain financing, the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

    Contact:
    Sharon Correia
    Alseres Pharmaceuticals, Inc
    508-497-2360 ext. 224
    scorreia@alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
10. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... OSF Ventures, the corporate ... largest start-up platform headquartered in Silicon Valley that connects startups to corporations and ... signed a three-year agreement to be a corporate sponsor of Plug and Play’s ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... from 140 Buzzies users who entered metrics into the product’s app. The ... The new data showed that within just 30 seconds of using Buzzies, people ...
(Date:1/23/2017)... ... 2017 , ... A Northwestern Pennsylvania addiction treatment center unveiled ... Rehabilitation & Recovery Center’s new website can be found at AlpineSpringsRehab.com . ... and retooled website. The treatment center has also revamped its social media strategy, ...
(Date:1/23/2017)... ... 2017 , ... DMG Productions is proud to announce the ... to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment will educate ... the limitations of fatigue monitoring technologies within the mining industry. Today SmartCap is ...
(Date:1/23/2017)... OR (PRWEB) , ... January 23, 2017 , ... Sharon ... to the air to educate listeners about the benefits of making new water infrastructure ... U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become a top ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... January 23, 2017 ArisGlobal, a ... sciences, announces agClinical 3.3, the latest version of its ... life science organizations to confidently and efficiently meet new ... manage the electronic trial master file so that compliance ... ...
(Date:1/23/2017)... , Jan. 23, 2017  Therabron Therapeutics, ... a new standard in respiratory care, today announced ... Orphan Medicinal Products has granted Orphan Drug Designation ... of Bronchiolitis Obliterans Syndrome (BOS).  "We ... from the EMA to treat patients diagnosed with ...
(Date:1/23/2017)... , Jan. 23, 2017 MouthWatch LLC announced today ... was ranked as the best intraoral camera on DentalCompare,s list ... #2 spot overall. The #1 product was the CollaPlug ... MouthWatch intraoral camera was "…incredibly popular because it is by ... has a small sticker price, it doesn,t sacrifice quality imaging." ...
Breaking Medicine Technology: